

Financial news for KITE dated on 2018-01-30: Gilead Sciences Outlook Brightens; Citi Upgrades

Financial news for KITE dated on 2017-12-13: ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More

Financial news for KITE dated on 2017-11-30: Maxim Explains Why Gilead Sciences Is A Now A Buy

Financial news for KITE dated on 2017-11-13: As Gilead's Outlook Dims, Argus Downgrades

Financial news for KITE dated on 2017-10-06: Life (Science) Lessons: The Hows And Whos To Play Biotech

Financial news for KITE dated on 2017-09-26: Gilead, Kite Pharma Report Expiration Of HSR Waiting Period

Financial news for KITE dated on 2017-09-07: Pro: Biotech Is The Hottest ETF Of 2017 With Plenty Of Upside Ahead

Financial news for KITE dated on 2017-09-05: Why It's Useful To Know A Company's Competitors When Trading

Financial news for KITE dated on 2017-09-01: Attention Biotech Investors: September Ushers In Another Slew Of PDUFA Catalysts

Financial news for KITE dated on 2017-09-01: Sell In May And Go Away? Doing So With These Stocks Was A Mistake

Financial news for KITE dated on 2017-08-31: A Sign Of Things To Come? Traders Are Betting On More Biotech Mergers

Financial news for KITE dated on 2017-08-31: iShares NASDAQ Biotech ETF At Highest Since Level Since December 2015

Financial news for KITE dated on 2017-08-31: Street Puts Stamp Of Approval On Gilead's Kite Pharma Takeover

Financial news for KITE dated on 2017-08-31: Gilead Gets An Upgrade Amid 'Game-Changing' Kite Deal

Financial news for KITE dated on 2017-08-30: The Market In 5 Minutes

Financial news for KITE dated on 2017-08-30: Brian Stutland Sees Unusual Options Activity In Juno Therapeutics

Financial news for KITE dated on 2017-08-29: Analysts Weigh In On Gilead-Kite Pharma Deal

Financial news for KITE dated on 2017-08-29: Juno Therapeutics Adds To Monday's Gain After Wedbush Upgrade

Financial news for KITE dated on 2017-08-29: 5 Biggest Price Target Changes For Tuesday

Financial news for KITE dated on 2017-08-29: Benzinga's Top Upgrades, Downgrades For August 29, 2017

Financial news for KITE dated on 2017-08-29: The Market In 5 Minutes

Financial news for KITE dated on 2017-08-29: Wall Street's M&A Chatter From August 28: Gilead-Kite Pharma, Enzymotec-Frutarom, MaxPoint-Valassis

Financial news for KITE dated on 2017-08-29: Wedbush Upgrades Kite Pharma to Neutral

Financial news for KITE dated on 2017-08-29: Canaccord Genuity Downgrades Kite Pharma to Hold

Financial news for KITE dated on 2017-08-28: Mid-Afternoon Market Update: IXYS Surges On Acquisition News; Uni-Pixel Shares Plunge

Financial news for KITE dated on 2017-08-28: Kite Pharma Receiving Multiple Downgrades Following Acquisition From Gilead, One Downgrade From Buy To Hold Via Suntrust and BTIG Downgrades Shares From Buy To Neutral

Financial news for KITE dated on 2017-08-28: 18 Biggest Mid-Day Gainers For Monday

Financial news for KITE dated on 2017-08-28: Mid-Day Market Update: Crude Oil Down

2.5%; MaxPoint Interactive Shares Spike Higher

Financial news for KITE dated on 2017-08-28: Juno Therapeutics Jumps 17% After Gilead's Purchase Of Kite Pharma

Financial news for KITE dated on 2017-08-28: Mid-Morning Market Update: Markets Mostly Higher; Gilead Sciences To Buy Kite Pharma

Financial news for KITE dated on 2017-08-28: Gilead Seeks Diversification Into Immuno-oncology Space With \$11.9 Billion Kite Pharma Acquisition

Financial news for KITE dated on 2017-08-28: 25 Stocks Moving In Monday's Pre-Market Session

Financial news for KITE dated on 2017-08-28: Kite Pharma Shares Resume Trading at \$177.95

Financial news for KITE dated on 2017-08-28: Kite Pharma to Resume at 7:30 AM ET

Financial news for KITE dated on 2017-08-28: A Peek Into The Markets: U.S. Stock Futures Edge Lower Ahead Of International Trade Data

Financial news for KITE dated on 2017-08-28: Gilead to Acquire Kite Pharma for \$11.9B Cash, \$180/Share

Financial news for KITE dated on 2017-08-28: Kite Pharma Halted, News Pending

Financial news for KITE dated on 2017-08-28: Gilead to Acquire Kite Pharma for \$180/Share According to Dow Jones

Financial news for KITE dated on 2017-08-28: Gilead to Buy Kite Pharma for ~\$11B in Cash -DJ

Financial news for KITE dated on 2017-08-25: Lightning Round: Jim Cramer Shares His Thoughts On Kite Pharma, Bank Of America And More

Financial news for KITE dated on 2017-08-17: Kite Pharma Highlights Publication Of Responses In Patients With Metastatic Solid Tumors Treated With MAGE A3: Study Showed 'the Potential of TCR Engineered T-Cell Therapy to Induce Remissions in Solid Tumors'

Financial news for KITE dated on 2017-08-15: Kite Pharma: Sky's The Limit

Financial news for KITE dated on 2017-08-14: 13F From Omega Shows New 200K Shares Position In L Brands, New 300K Share Stake In Gardner Denver, 1M Share Stake In Intelsat; Reduced Position In Hess From 1.164M Shares To 983.8K Shares; Exited Position In Kite Pharma, Humana, Iberiabank

Financial news for KITE dated on 2017-08-09: Canaccord Genuity Growth Conference Begins Today, Presenters Include Wayfair, Rocky Brands, NantKwest, Sierra Wireless, Aerie Pharma, Kite Pharma, Mulesoft, Zendesk, Paycom, and Cirrus Logic

Financial news for KITE dated on 2017-08-08: Kite Pharma Reports Q2 Adj. EPS \$(1.50) vs \$(1.98) Est., Sales \$10.1M vs \$9.6M Est.

Financial news for KITE dated on 2017-08-08: Kite Submits Investigational New Drug Application for KITE-585, Anti-BCMA CAR-T Therapy Candidate for Multiple Myeloma

Financial news for KITE dated on 2017-08-07: Kite Pharma Reports Initiation Of Axicabtagene Ciloleucel CAR-T Program In EU

Financial news for KITE dated on 2017-08-03: Kite Reports Landmark Study of Refractory Aggressive Non-Hodgkin Lymphoma Outcomes Published in the Journal BLOOD

Financial news for KITE dated on 2017-08-02: Kite Doses Initial Patient in the Phase 2 Trial of Axicabtagene Ciloleucel in Indolent B-Cell Non-Hodgkin Lymphoma

Financial news for KITE dated on 2017-07-31: Kite Pharma Submits Marking Authorization Application to the European Medicines Agency for Axicabtagene Ciloleucel

Financial news for KITE dated on 2017-07-28: Lightning Round: Jim Cramer Shares His Thoughts On Freeport-McMoRan, Pfizer And More

Financial news for KITE dated on 2017-07-13: Maxim Group Downgrades Kite Pharma to Hold

Financial news for KITE dated on 2017-07-13: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for KITE dated on 2017-07-10: Jefferies Raises Price Target On Kite

Pharma From \$101 To \$121 On Reduced Regulatory Risks

Financial news for KITE dated on 2017-06-30: After Bluebird's 75% Gain In 2017, Analysts At BTIG Downgrade To Neutral

Financial news for KITE dated on 2017-06-28: Kite Pharma Announces USPTO Will Issue Ex Parte Reexamination Certificate For Patent No. 7,741,765

Financial news for KITE dated on 2017-06-27: Kite Pharma A Top Pick Ahead Of Axi-Cel Launch

Financial news for KITE dated on 2017-06-20: Companies Holding Shareholder Meetings Today Include: Bankrate, Farmer Brothers, Five Below, Kite Pharma, Cavium, New York & Co., Ooma, Pure Storage, STMicroelectronics, and Workday

Financial news for KITE dated on 2017-06-09: Vetr Downgrades Kite Pharma As It Nears Resistance

Financial news for KITE dated on 2017-06-08: 15 Biggest Mid-Day Gainers For Thursday

Financial news for KITE dated on 2017-06-08: The Only Bullish Scenario For Juno Therapeutics: Its CEO May Get Fired

Financial news for KITE dated on 2017-06-08: Benzinga's Top Upgrades, Downgrades For June 8, 2017

Financial news for KITE dated on 2017-06-08: Key Reasons BTIG Just Upgraded Kite Pharma

Financial news for KITE dated on 2017-06-08: BTIG Research Upgrades Kite Pharma to Buy

Financial news for KITE dated on 2017-06-07: Kite Pharma Shares Dip Lower Over Last Few Mins, Pullback from Session High As Traders Circulating Word Novartis Has Said Co.'s Manufacturing Improved To 97% In The Last 30 Patients

Financial news for KITE dated on 2017-06-07: Jefferies Health Care Conference Continues Today, Presenters Include Teva, WAVE Life Sciences, Envision Healthcare, NantKwest, Ignyta, Puma Biotech, and Kite Pharma

Financial news for KITE dated on 2017-06-05: Kite Reports Phase 1 ZUMA-3 Trial of KTE-C19 Showed 73% Of Patients Achieved Complete Remission of High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia

Financial news for KITE dated on 2017-05-26: Kite Receives U.S. Food and Drug Administration Priority Review for Axicabtagene Ciloleucel, PDUFA Set For Nov. 29th 2017; BLA Submission Based ON Primary Analysis OF ZUMA-1 Phase 2 Trial

Financial news for KITE dated on 2017-05-09: Adam Feuerstein Tweets: \$KITE CEO bought 17K shares in the open market today.

Financial news for KITE dated on 2017-05-09: Kite Pharma CEO Belldegrün Buys 17,000 Shares @ Avg Price: \$68.57 -Form 4

Financial news for KITE dated on 2017-05-09: Benzinga's Top Upgrades, Downgrades For May 9, 2017

Financial news for KITE dated on 2017-05-09: Wedbush Downgrades Kite Pharma to Underperform

Financial news for KITE dated on 2017-05-08: Hearing Kite Pharma Shares Downgraded to Market Perform by Raymond James

Financial news for KITE dated on 2017-05-08: 12 Biggest Mid-Day Losers For Monday

Financial news for KITE dated on 2017-05-08: Analyst: Kite Pharma's CAR-T Patient Death, Stock Selloff Is A Buying Opportunity

Financial news for KITE dated on 2017-05-08: UPDATE: Cowen on Kite Says Would Be Aggressive Buyers; Stock Down ~13%

Financial news for KITE dated on 2017-05-08: UPDATE: Cowen Analyst on Kite Calls Patient Death 'Non Event,' Says Death Will Not Impact Drugs Opportunity 'At All'

Financial news for KITE dated on 2017-05-08: Cowen's Eric Schmidt Defending Kite

Financial news for KITE dated on 2017-05-08: Adam Feuerstein Tweets: Kite Pharma Discloses CAR-T Patient Death, Rattling Investors --> [thestreet.com/story/14123564...](http://thestreet.com/story/14123564...)

Financial news for KITE dated on 2017-05-08: Mid-Morning Market Update: Markets Edge Lower; Tyson Profit Misses Estimates

Financial news for KITE dated on 2017-05-08: Kite Pharma Sees FY17 Net Cash Burn \$325M-\$340M, GAAP OpEx \$490M-\$515M

Financial news for KITE dated on 2017-05-08: Kite Reports Q1 EPS \$(1.28) vs \$(0.60) In Prior Year Period, Sales \$9.8M vs \$5.1M In Prior Year Period

Financial news for KITE dated on 2017-04-20: Benzinga's Option Alert Recap From April 20

Financial news for KITE dated on 2017-04-20: Option Alert: Kite Pharma Jul 100 Calls: 634 @ ASK \$1.55: 2134 traded vs 304 OI: Earnings 5/9 Before Open [est] \$79.19 Ref

Financial news for KITE dated on 2017-04-19: Option Alert: Kite Pharma Jul 90.0 Calls: 2500 @ ASK \$3.70: 2501 traded vs 1184 OI: Earnings 5/9 Before Open [est] \$79.91 Ref

Financial news for KITE dated on 2017-04-05: TheStreet's Adam Feuerstein Tweets '\$NVS Keeps 'JULIET' Study Results Close as Investors and Rival \$KITE'

Financial news for KITE dated on 2017-04-04: Kite Pharma Issues Preclinical Data from KITE-585 at AACR: 'Phase 1 Clinical Study of KITE-585 in Patients with Multiple Myeloma Planned for 2017'

Financial news for KITE dated on 2017-04-03: 15 Biggest Mid-Day Gainers For Monday

Financial news for KITE dated on 2017-04-03: PreMarket Prep Recap: The Most Important Macro Indicators

Financial news for KITE dated on 2017-04-03: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for KITE dated on 2017-04-02: Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at AACR 2017

Financial news for KITE dated on 2017-03-31: Kite Completes Submission of U.S. BLA for Axicabtagene Ciloleucel as the First CAR-T Therapy for the Treatment of Patients With Aggressive NHL

Financial news for KITE dated on 2017-03-29: Watch These 8 Huge Put Purchases In Wednesday Trade

Financial news for KITE dated on 2017-03-28: Benzinga's Option Alert Recap From March 28

Financial news for KITE dated on 2017-03-28: Option Alert: Kite Pharma Apr 65.0 Puts Sweep: 646 @ ASK \$0.75: 686 traded vs 2489 OI: Earnings 5/9 Before Open (est) \$78.61 Ref

Financial news for KITE dated on 2017-03-14: Kite Pharma Says 50% Of Patients In Ongoing Complete Remission With Duration Ranging From 7 to 24 Months Following Anti-CD19 CAR T-Cell Therapy and Low Dose Chemotherapy

Financial news for KITE dated on 2017-03-14: Gilead Looking To Buy Incyte? It Makes Sense

Financial news for KITE dated on 2017-03-13: Standpoint Research Downgrades Kite Pharma To Hold

Financial news for KITE dated on 2017-03-07: Cowen Annual Healthcare Conference Continues Today; Presenters Include Regulus, Eli Lilly, Oculus, DexCom, Illumina, Allergan, Kite Pharma, Pfizer, and bluebird bio

Financial news for KITE dated on 2017-03-06: RBC Hints At Potential M&A For Kite Pharma

Financial news for KITE dated on 2017-03-05: Richard L. Wang Named CEO of Fosun Kite Biotechnology Co., Ltd.

Financial news for KITE dated on 2017-03-03: Benzinga's Top Upgrades, Downgrades For March 3, 2017

Financial news for KITE dated on 2017-03-03: Stifel Nicolaus Downgrades Kite Pharma to Hold

Financial news for KITE dated on 2017-03-02: Benzinga's Option Alert Recap From March

Financial news for KITE dated on 2017-03-02: Option Alert: Kite Pharma Apr \$90 Call; 2000 @Bid @\$1.36

Financial news for KITE dated on 2017-03-02: 20 Biggest Mid-Day Losers For Thursday

Financial news for KITE dated on 2017-03-02: 8 Biggest Price Target Changes For Thursday

Financial news for KITE dated on 2017-03-02: Benzinga's Top Upgrades, Downgrades For March 2, 2017

Financial news for KITE dated on 2017-03-02: The Market In 5 Minutes

Financial news for KITE dated on 2017-03-02: Kite Prices 4.75M Shares At \$75/Share

Financial news for KITE dated on 2017-03-02: Wedbush Asks: How Does Kite Pharma's ZUMA-1 Compare To Juno's TRANSCEND?

Financial news for KITE dated on 2017-03-02: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for KITE dated on 2017-03-02: Citigroup Downgrades Kite Pharma to Neutral, Raises Price Target to \$87.00

Financial news for KITE dated on 2017-03-02: Kite Announces Commencement of 4.75M Share Offering

Financial news for KITE dated on 2017-03-01: Vetr Downgrades The High-Flying Kite

Financial news for KITE dated on 2017-02-28: Kite Pharma On A Rip, Even Before Positive Quarter Print

Financial news for KITE dated on 2017-02-28: Standpoint Research Reiterates Buy on Kite Pharma, Maintains \$85.00 Price Target

Financial news for KITE dated on 2017-02-28: Kite Pharma Resumes Trade, Up 14% At \$65

Financial news for KITE dated on 2017-02-28: Kite Pharma Reports Q4 EPS \$(1.31) vs. \$(1.75), Sales \$4.9M vs. \$5.6M Est.

Financial news for KITE dated on 2017-02-28: Adam Feuerstein @adamfeuerstein Tweet: \$KITE -- Seems like 6-month CR rate in DLBCL held up well compared to what we saw at 3 months. 31% from 33%. Agree? No?

Financial news for KITE dated on 2017-02-28: Kite Pharma Meets Primary Endpoint of Objective Response Rate, Announces Positive Topline Results

Financial news for KITE dated on 2017-02-23: Benzinga's Option Alert Recap From February 23

Financial news for KITE dated on 2017-02-23: Option Alert: Kite Pharma Mar 60.0 Calls: 700 @ ASK \$1.30: 700 traded vs 919 OI: Earnings 2/28 Before Open (est) \$52.53 Ref

Financial news for KITE dated on 2017-02-22: Wells Fargo Initiates Coverage On Kite Pharma At Market Perform

Financial news for KITE dated on 2017-02-17: Watch These 5 Huge Put Purchases In Friday Trade

Financial news for KITE dated on 2017-02-16: Benzinga's Option Alert Recap From February 16

Financial news for KITE dated on 2017-02-16: Option Alert: KITE Mar 50.0 Puts Sweep: 2000 @ ASK \$3.031: 2003 traded vs 422 OI: Earnings 2/28 Before Open (est) \$54.54 Ref

Financial news for KITE dated on 2017-02-01: Wedbush Initiates Coverage On Kite Pharma at Neutral, Announces \$46.00 Target

Financial news for KITE dated on 2017-01-26: J.P. Morgan Reports 6% Stake In Kite Pharma

Financial news for KITE dated on 2017-01-19: Jim Cramer Advises Viewers On Tesla, CNO Financial, Sprint And Kite Pharma

Financial news for KITE dated on 2017-01-18: Option Alert: Kite Pharma Feb 40.0 Puts:

1000 @ ASK \$1.70: 1021 traded vs 527 OI: Earnings 2/28 Before Open (est) \$47.25  
Ref

Financial news for KITE dated on 2017-01-09: Kite Pharma, Daiichi Sankyo Partner To Develop and Commercialize KTE-C19 In Japan; Upfront and Milestone Payments Total \$250 Million Plus Double Digit Sales Royalties

Financial news for KITE dated on 2017-01-04: Benzinga's Top Upgrades, Downgrades For January 4, 2017

Financial news for KITE dated on 2017-01-03: Kite Pharma Submits Investigational New Drug (IND) Application for KITE-718

Financial news for KITE dated on 2016-12-23: 15 Stocks With The Highest Forecast Sales Growth

Financial news for KITE dated on 2016-12-19: Juno Therapeutics Defeats Kite Pharma's Challenge to CAR T-Cell Patent

Financial news for KITE dated on 2016-12-19: Kite Pharma Announces Successful Defense of Roberts Patent and Intent to Appeal U.S. Patent and Trademark Office Decision on a Narrow Patent Focused on Select CD28 CAR-T Products

Financial news for KITE dated on 2016-12-07: Why Kite Pharma Investors Should Expect Lymphoma Treatment FDA Approval In 2017

Financial news for KITE dated on 2016-12-06: Technical Alert: Kite Pharma Surrenders Monday's Gain

Financial news for KITE dated on 2016-12-06: Kite Pharma Reports Results of Multi-Center Pivotal ZUMA-1 Trial of KTE-C19: 76% of Patients with Diffuse Large B-Cell Lymphoma Achieved Objective Response (p < 0.0001), 47% Complete Remissions at Pre-specified Interim Analysis

Financial news for KITE dated on 2016-12-05: American Society Of Hematology (ASH) Meeting Presenters Tonight Include Karyopharm, bluebird bio, Alnylam, Juno Therapeutics, Stemline Therapeutics, Kite Pharma, Beigene, & Prothena

Financial news for KITE dated on 2016-12-05: What Is The ASH Conference And Why Should Biotech Investors Care?

Financial news for KITE dated on 2016-12-05: Technical Alert: Kite Pharma Higher

Financial news for KITE dated on 2016-12-05: CNBC's Meg Tirrell Tweets: #ASH16 stocks looking largely opposite of last year. So far: \$KITE +9.4% \$JUNO +6.6% \$ONCE +2.5% On flip side: \$GBT -3.3% \$AGIO -12%

Financial news for KITE dated on 2016-12-05: Kite Pharma Initiates Rolling Submission of U.S. Biologics License Application (BLA) for KTE-C19, its Investigational anti-CD19 CAR-T Therapy, for the Treatment of Patients with Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Financial news for KITE dated on 2016-12-01: Bluebird News A Positive For Juno, Kite Pharma

Financial news for KITE dated on 2016-11-23: Biotech Down In Early Trading: PDL BioPharma 15%, Eli Lilly 13%, Biogen, 6%, Cellectis, Insys 5.5%, Dynavax, Kite 5%

Financial news for KITE dated on 2016-11-21: Benzinga's Top Initiations

Financial news for KITE dated on 2016-11-21: H.C. Wainwright Initiates Coverage On Kite Pharma at Buy, Announces \$78.00

Financial news for KITE dated on 2016-11-16: Stifel Healthcare Conference Continues Today

Financial news for KITE dated on 2016-11-09: Kite Pharma Reports Q3 EPS \$(1.49) vs. Est. \$(1.62), Rev. \$7.3M vs. Est. \$4.94M

Financial news for KITE dated on 2016-11-04: BTIG Is No Longer Selling Juno Therapeutics Stock

Financial news for KITE dated on 2016-10-19: Kite Pharma Unveils Four New Clinical Programs; Highlights KTE-C19 Expansion Studies

Financial news for KITE dated on 2016-10-18: Kite Pharma Holding Investor Day At 12 noon EST

Financial news for KITE dated on 2016-10-17: 18 Stocks Moving In Monday's Pre-Market

## Session

Financial news for KITE dated on 2016-10-10: Safety Remains A Top Concern For Kite Pharma After Positive Phase 1 ZUMA-1 Data

Financial news for KITE dated on 2016-10-07: Following Kite Pharma's Positive Top-Line Data, Focus Turns To Commercial Outlook

Financial news for KITE dated on 2016-10-07: Kite Pharma Says ZUMA-1 Phase 1 Data for KTE-C19 Showed '43 Percent Complete Remission Rate Continues at 12-Month Follow-Up'

Financial news for KITE dated on 2016-10-07: European Society For Medical Oncology Conference Commences Today (Oct.7 Thru Oct. 11)

Financial news for KITE dated on 2016-10-06: Kite Pharma Reports Initiation of Phase 1b/2 Combo Study for KTE-C19, Atezolizumab in Patients with DLBCL

Financial news for KITE dated on 2016-10-04: Abstracts Expected Wednesday From Companies Presenting At The European Society For Medical Oncology Conf. Beginning Oct. 7th, Including From Karyopharm Therapeutics, Kite Pharma And Clovis Oncology

Financial news for KITE dated on 2016-09-27: Technical Alert: Kite Pharma Finds Resistance And Retreats

Financial news for KITE dated on 2016-09-27: Kite Pharma's Initial ZUMA Data 'Solid'; Barclays Raises Target To \$65

Financial news for KITE dated on 2016-09-27: 15 Biggest Mid-Day Gainers For Tuesday

Financial news for KITE dated on 2016-09-27: Kite Pharma Spiking After Release Of Positive Clinical Data

Financial news for KITE dated on 2016-09-27: Benzinga's Volume Movers

Financial news for KITE dated on 2016-09-27: Mid-Morning Market Update: Markets Open Higher; FactSet Misses Q4 Views

Financial news for KITE dated on 2016-09-27: Juno Therapeutics Viewed As A Sympathy Play On Kite Pharma's KTE-C19

Financial news for KITE dated on 2016-09-27: 15 Stocks Moving In Tuesday's Pre-Market Session

Financial news for KITE dated on 2016-09-27: Kite Pharma +11.8% Premarket @\$61.50; Co Announced Positive Topline KTE-C19 Data from ZUMA-1 Pivotal Trial in Patients with Aggressive Non-Hodgkin Lymphoma on Monday

Financial news for KITE dated on 2016-09-26: 3 After-Hours Movers: Earnings & Clinical Data Pushing Stocks Up

Financial news for KITE dated on 2016-09-26: Kite Pharma Shares Resume, Now Up 16%

Financial news for KITE dated on 2016-09-26: Kite Pharma Shares to Resume Trade at 4:30 p.m. EDT

Financial news for KITE dated on 2016-09-26: Juno Up 10% After Hours In Sympathy To Kite Pharma Top-Line Results

Financial news for KITE dated on 2016-09-26: UPDATE: Data Is From KTE-C19 Data From ZUMA-1 Pivotal Trial In NHL

Financial news for KITE dated on 2016-09-26: Kite Pharma Study Met Primary Endpoint of Objective Response Rate (p<0.0001) at Interim Analysis

Financial news for KITE dated on 2016-09-26: Kite Pharma Shares Halted News Pending

Financial news for KITE dated on 2016-09-20: Kite Pharma Reports Exclusive License Deal with NIH for Multiple Neoantigen Directed TCR Product Candidates to Treat Solid Tumors Expressing Mutated KRAS

Financial news for KITE dated on 2016-08-31: BTIG Is 'Generally Skeptical' On Kite Pharma Expectations

Financial news for KITE dated on 2016-08-30: BTIG Research Initiates Coverage on Kite Pharma at Neutral

Financial news for KITE dated on 2016-08-30: Vetr Crowd Slowly Turning Positive On Kite Pharma, Now Rates It A Buy

Financial news for KITE dated on 2016-08-08: Kite Pharma Reports Q2 EPS \$(0.91) vs. Est. \$(1.21), Rev. \$4.8M vs. Est. \$4.86M

Financial news for KITE dated on 2016-07-25: Kite Pharma Licenses Enabling Technology for the Development of Off-the-Shelf Allogeneic T-Cell Therapies, Kite To Receive Exclusive Rights To Develop And Commercialize T-Cell Products In Oncology

Financial news for KITE dated on 2016-07-13: 8 Biggest Mid-Day Gainers For Wednesday

Financial news for KITE dated on 2016-07-13: Juno Therapeutics Soars 25% After ROCKET Phase 2 Rocket Trial Resumption

Financial news for KITE dated on 2016-07-13: 12 Stocks Moving In Wednesday's Pre-Market Session

Financial news for KITE dated on 2016-07-11: Mid-Afternoon Market Update: Crude Oil Down Over 1%; BioLife Solutions Shares Move Higher

Financial news for KITE dated on 2016-07-11: 10 Biggest Mid-Day Gainers For Monday

Financial news for KITE dated on 2016-07-11: Mid-Day Market Update: Dow Surges Over 100 Points; Sagent Pharmaceuticals Shares Spike Higher

Financial news for KITE dated on 2016-07-11: Mid-Morning Market Update: Markets Open Higher; Bank Of The Ozarks Profit Tops Views

Financial news for KITE dated on 2016-07-11: 11 Stocks Moving In Monday's Pre-Market Session

Financial news for KITE dated on 2016-07-08: 8 Biggest Mid-Day Losers For Friday

Financial news for KITE dated on 2016-07-08: These Biotechs Are Getting Crushed Following Juno's Cancer Drug Hold

Financial news for KITE dated on 2016-07-08: 10 Stocks Moving In Friday's Pre-Market Session

Financial news for KITE dated on 2016-07-07: Kite Pharma Completes Enrollment of All Patients with Diffuse Large B-Cell Lymphoma in Pivotal Multi-Center Phase 2 Study of KTE-C19

Financial news for KITE dated on 2016-07-07: Kite Pharma Shares Falling In Sympathy To Juno Clinical Hold

Financial news for KITE dated on 2016-07-06: Barclays Initiates 2 Cellular Cancer Therapy Plays With Equal-Weight Rating

Financial news for KITE dated on 2016-07-06: Barclays Initiates Coverage on Kite Pharma at Equal-weight, Announces \$58.00 PT

Financial news for KITE dated on 2016-06-20: Kite Pharma Opens State-of-the-Art T-Cell Therapy Manufacturing Facility

Financial news for KITE dated on 2016-06-20: Kite Pharma Expands Development of T-Cell Receptor Therapies Targeting HPV-Associated Cancers in Partnership with the National Cancer Institute

Financial news for KITE dated on 2016-06-06: Kite Pharma Rallies Off Positive Drug Results, hits Highest Level In 5 Months

Financial news for KITE dated on 2016-06-06: Kite Pharma Announces the First Meta-Analysis of Outcomes in Chemorefractory Diffuse Large B-Cell Lymphoma, Overall Response Rate Of 26% With Only 8% Achieving Complete Response

Financial news for KITE dated on 2016-06-06: Kite/NCI Anti-CD19 CAR T-Cell Therapy Demonstrates Durable Complete Remissions in Advanced Non-Hodgkin Lymphoma, 9 of 19 Patients Achieved Complete Responses With Duration Of 7-20 Months

Financial news for KITE dated on 2016-06-06: Kite Pharma Reports Ongoing Responses Of ZUMA-1 Patients, Ways Treatment Showed ORR Of 71%, Complete Response Rate 57% In 7 Patients

Financial news for KITE dated on 2016-06-02: Kite Pharma Takes Off

Financial news for KITE dated on 2016-06-02: Benzinga's Top Initiations

Financial news for KITE dated on 2016-06-02: Raymond James Initiates Coverage on Kite Pharma at Outperform



Financial news for KITE dated on 2016-06-02: Kite Pharma, Cell Design Labs Report Exclusive Research Collaboration Using Molecular Switches For CAR T-Cell Immunotherapies

Financial news for KITE dated on 2016-06-01: 5 Stocks Moving Higher in Wednesday's Afterhours Session

Financial news for KITE dated on 2016-06-01: Kite Pharma Granted Access to Priority Medicines (PRIME) Regulatory Support for KTE-C19 in the Treatment of Chemorefractory Diffuse Large B-Cell Lymphoma (DLBCL)

Financial news for KITE dated on 2016-05-16: Kite Pharma Names Paul L. Jenkinson as CFO

Financial news for KITE dated on 2016-05-09: Kite Pharma Q1 EPS (\$0.90) vs (\$1.09) est, Revenue \$5.13M vs \$4.61M est

Financial news for KITE dated on 2016-05-02: Kite Pharma Reports FDA Orphan Drug Designations for KTE-C19 in Five Additional Indications

Financial news for KITE dated on 2016-04-26: BioRunUp @BioRunUp Tweet: \$KITE with three ODDs granted by the FDA. No company PR yet

Financial news for KITE dated on 2016-04-20: Kite Pharma Gains 2% After Management Provides Update To A Phase 1 Study

Financial news for KITE dated on 2016-04-20: 10 Stocks Moving In Wednesday's Pre-Market Session

Financial news for KITE dated on 2016-04-19: Kite Pharma Presents Updated Phase 1 Results from ZUMA-1 at AACR

Financial news for KITE dated on 2016-04-18: Kite Pharma Falls 6%, Co. Confirms Review Of All Facilities Involving Sterile Material

Financial news for KITE dated on 2016-04-18: 10 Stocks Moving In Monday's Pre-Market Session

Financial news for KITE dated on 2016-03-29: Children's Hospital LA Announces Will Begin ZUMA 4 Trial, in Conjunction with Kite Pharma, Related to Treatment for Kids with Treatment-Resistant Leukemia

Financial news for KITE dated on 2016-03-17: Kite, Juno 'Well Positioned' To Win From AACR

Financial news for KITE dated on 2016-03-17: Kite Pharma Reports Clinical Partnership To Evaluate 2 Novel Immunotherapies For Non-Hodgkin Lymphoma Patients

Financial news for KITE dated on 2016-03-16: Kite Pharma Reports Clinical, Manufacturing KTE-C19 and MAGE-A4 Product Candidates At AACR

Financial news for KITE dated on 2016-03-02: Kite Pharma Spikes to High on Volume

Financial news for KITE dated on 2016-03-01: Jefferies Maintains Buy on Kite Pharma, Lowers PT to \$75.00

Financial news for KITE dated on 2016-03-01: Stifel Nicolaus Maintains Buy on Kite Pharma, Lowers PT to \$63.00

Financial news for KITE dated on 2016-02-29: Kite Pharma Reports Q4 EPS \$(0.51) Vs Est \$(0.71), Sales \$4.89M Vs Est \$4.54M

Financial news for KITE dated on 2016-02-25: Citigroup Initiates Coverage on Kite Pharma at Buy

Financial news for KITE dated on 2016-02-02: Benzinga's Top Initiations

Financial news for KITE dated on 2016-02-02: RBC Capital Initiates Coverage on Kite Pharma at Outperform, Announces \$85.00 PT

Financial news for KITE dated on 2016-01-29: Benzinga's Top Initiations

Financial news for KITE dated on 2016-01-29: SunTrust Robinson Humphrey Initiates Coverage on Kite Pharma at Buy, Announces \$70.00 PT

Financial news for KITE dated on 2016-01-26: Kite Pharma Falls 6%; May be Attributed in Part to Report in Journal of Clinical Oncology

Financial news for KITE dated on 2016-01-19: FBR Upgrades Kite Pharma, Sees 35%

Upside

Financial news for KITE dated on 2016-01-19: FBR Capital Upgrades Kite Pharma to Outperform

Financial news for KITE dated on 2016-01-13: Kite Pharma, Leiden University Medical Center Report Signing of Research, License Deal for T-Cell Receptors Targeting HPV-Associated Cancers

Financial news for KITE dated on 2016-01-12: Fast Money Traders Share Their Biotech Picks

Financial news for KITE dated on 2016-01-07: Napodano: Here Is Actinium's Place Among The CAR-T Hype & Radiopharma Busts

Financial news for KITE dated on 2016-01-07: Kite Pharma Reports Expansion of Clinical Deal with NCI for Next-Gen CAR Programs to Treat B-Cell Malignancies

Financial news for KITE dated on 2015-12-17: The Top 20 Wall Street Analysts Of 2015

Financial news for KITE dated on 2015-12-15: Standpoint Research Upgrades Kite Pharma to Buy

Financial news for KITE dated on 2015-12-10: Kite Pharma Prices 3.625M Shares at \$69/Share for Gross Proceeds ~\$250.1M

Financial news for KITE dated on 2015-12-08: Kite Pharma Reports Offering of ~\$250M in Common Shares

Financial news for KITE dated on 2015-12-08: Vetr Crowd Sees Juno Therapeutics As A Five-Star Stock

Financial news for KITE dated on 2015-12-08: FBR's Ed White Raises Target on Kite Pharma from \$65 to \$72 Amid Increased Confidence in Co.'s KTE-C19 Therapy; Maintains Market Perform Rating

Financial news for KITE dated on 2015-12-07: Kite Pharma Says Will Issues Results of Anti-CD19 CAR T Cell Therapy at ASH Meeting

Financial news for KITE dated on 2015-12-07: Kite Pharma Shows Phase 1 Results From ZUMA-1 at the 57th American Society of Hematology (ASH) Annual Meeting

Financial news for KITE dated on 2015-12-07: US Stock Futures Edge Higher; Crude Oil Slides

Financial news for KITE dated on 2015-12-07: Kite Pharma Announces Breakthrough Therapy Designation for KTE-C19

Financial news for KITE dated on 2015-12-07: Kite Pharma Receives FDA Breakthrough Therapy Designation for KTE-C19 for the Treatment of Refractory, Aggressive Non Hodgkin Lymphoma (NHL)

Financial news for KITE dated on 2015-12-03: Kite Pharma and GE Global Research Announce Strategic Collaboration to Automate Manufacturing of Engineered T Cell Therapies

Financial news for KITE dated on 2015-12-03: Kite Pharma, GE Global Research Report Strategic Collaboration to Automate Manufacturing of Engineered T Cell Therapies; Terms Of Agreement Not Disclosed

Financial news for KITE dated on 2015-12-02: Kite Pharma Initiates the ZUMA-3 Study to Support Registration of KTE-C19 for Relapsed or Refractory (r/r) Acute Lymphoblastic Leukemia (ALL) in Adult Subjects

Financial news for KITE dated on 2015-11-18: Goldman Sees 2016 'Flight To Quality' In These Biotech Stocks

Financial news for KITE dated on 2015-11-18: Goldman Sachs Initiates Coverage on Kite Pharma at Buy, Announces \$111.00 PT

Financial news for KITE dated on 2015-11-14: Ronnie Moas Downgrades Kite Pharma, Sees \$100 Stock Price Through 2018

Financial news for KITE dated on 2015-11-13: Standpoint Research Downgrades Kite Pharma to Hold

Financial news for KITE dated on 2015-11-12: Kite Pharma Reports Q3 Adj. EPS \$(0.38) vs \$(0.64) Est., Sales \$5.1M vs \$4.1M Est.

Financial news for KITE dated on 2015-11-09: Kite Pharma Starts Phase 2 Clinical Study of KTE-C19 in Patients With Relapsed or Refractory Mantle Cell Lymphoma to Support Registration for a Second Indication

Financial news for KITE dated on 2015-11-05: Andy Biotech Tweets: #ASH15 Abstracts. Tweet Has Links To Each Biotech Company's Abstract

Financial news for KITE dated on 2015-11-05: Kite Pharma to Present Four Abstracts, including Safety and Efficacy Data from the KTE-C19 Phase 1 Study in Patients with Refractory, Aggressive NHL , at the 57th American Society of Hematology Annual Meeting

Financial news for KITE dated on 2015-10-27: Kite Pharma, Alpine Immune Sciences Report Research Collab, License Deal

Financial news for KITE dated on 2015-10-22: Ferrari Races Into Its First ETF Home

Financial news for KITE dated on 2015-10-20: Kite Pharma Announces Exclusive License with the National Institutes of Health for T Cell Receptor (TCR)-Based Products to Treat Tumors Expressing MAGE

Financial news for KITE dated on 2015-10-15: Kite Pharma Receives Positive Opinions for Orphan Drug Designation in the European Union (EU) for KTE-C19 in Three Additional Hematological Indications

Financial news for KITE dated on 2015-10-05: 13G Filing from Viking Global on Kite Pharma Shows New 6.1% Stake

Financial news for KITE dated on 2015-10-01: Kite Pharma Announces Peer-Reviewed Publication of HPV-16 E6 to Treat HPV-Associated Cancers

Financial news for KITE dated on 2015-09-14: Kite Pharma Expands Collaboration With Netherlands Cancer Institute (NKI)

Financial news for KITE dated on 2015-09-11: Kite Pharma Receives Positive Opinion for Orphan Drug Designation in the European Union for KTE-C19, Kite's Lead Cancer T-Cell Immunotherapy

Financial news for KITE dated on 2015-09-08: A Portfolio To Support Cancer Treatments In Time For Prostate Cancer Awareness Month

Financial news for KITE dated on 2015-08-21: In new note to subscribers, CMT Christian Tharp making bet that 15-20% correction is coming

Financial news for KITE dated on 2015-08-20: 10 Biotech Stocks With Catalysts Coming Soon

Financial news for KITE dated on 2015-08-17: Kite Pharma Gets Off The Ground With Trial Update, New Buy Rating

Financial news for KITE dated on 2015-08-17: Kite Pharma Shares Up 5% Following Co. Update on KTE-C19 Trial; Standpoint's Moas Sees 'Good Entry Point,' Believes Share Price Potentially Heading Towards \$70 by Next Weekend

Financial news for KITE dated on 2015-08-17: Benzinga's Volume Movers

Financial news for KITE dated on 2015-08-17: Standpoint Research Initiates Coverage on Kite Pharma at Buy, Announces \$100.00 PT

Financial news for KITE dated on 2015-08-17: Kite Pharma Offers Update on KTE-C19 Trial, Says On Track to Advance to PIVOTAL Phase 2 Trial

Financial news for KITE dated on 2015-08-14: Kite Pharma Drops From The Sky

Financial news for KITE dated on 2015-08-10: Kite Pharma Reports Q2 GAAP Loss of \$0.48/Share, Sales \$4.4M vs \$2.5M Est.; FY15 Cash Burn Guidance Affirmed at \$100M-\$125M

Financial news for KITE dated on 2015-08-07: Roth Says Buy The Dip In This Biotech

Financial news for KITE dated on 2015-07-31: Kite Pharma Takes Flight And Retreats

Financial news for KITE dated on 2015-07-20: BofA Starts Collectis At Buy, Sees Plant Sciences As 'Hidden Gem'

Financial news for KITE dated on 2015-07-01: Kite Pharma and The Leukemia & Lymphoma Society Enter Into Collaboration to Enhance the Development of KTE-C19 in Refractory Aggressive Non-Hodgkin Lymphoma and Launch CAR T-Cell Therapy Educational Programs

Financial news for KITE dated on 2015-07-01: Fast Money Picks For July 1

Financial news for KITE dated on 2015-06-30: Morning Market Gainers

Financial news for KITE dated on 2015-06-30: Benzinga's Top #PreMarket Gainers

Financial news for KITE dated on 2015-06-29: Juno Therapeutics, Kite Pharma, Eleven Bio Lead Monday's After-Hours Movers

Financial news for KITE dated on 2015-06-24: Kite Pharma CEO: 'We Are Offering The Next Generation Immunotherapy'

Financial news for KITE dated on 2015-06-24: Kite Pharma Shares Its Vision: Here's How Wall Street Is Reacting

Financial news for KITE dated on 2015-06-24: Morning Market Gainers

Financial news for KITE dated on 2015-06-24: Benzinga's Top #PreMarket Gainers

Financial news for KITE dated on 2015-06-22: Kite Pharma and bluebird bio Announce Strategic Collaboration to Advance Second Generation TCR Cell Therapy Products to Treat HPV-Associated Cancers

Financial news for KITE dated on 2015-06-18: Maxim Group Initiates Coverage on Kite Pharma at Buy, nn \$87.00 PT

Financial news for KITE dated on 2015-06-16: Adimab, Kite Pharma Collaborate For Discovery Of Antibodies For T-Cell Therapies

Financial news for KITE dated on 2015-06-04: Moffitt Cancer Center Announces First Patient in Nation Treated With KTE-C19 in Kite Pharma's Clinical Trial for NHL

Financial news for KITE dated on 2015-05-29: Kite Pharma to Present Clinical Biomarkers From Patients Treated With Anti-CD19 Chimeric Antigen Receptor T Cell Therapy at the 2015 ASCO Annual Meeting

Financial news for KITE dated on 2015-05-21: Kite Pharma Reports That the First Patient in Its Phase 1/2 Clinical Trial Has Been Treated With KTE-C19, Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, for Refractory Aggressive Non-Hodgkin's Lymphoma

Financial news for KITE dated on 2015-05-16: After-Hours Movers Friday: Seventy Seven Energy, Kite Pharma

Financial news for KITE dated on 2015-05-15: Kite Pharma Reports Q1 Adj. Loss of \$0.20/Share May Not Compare to Gain of \$0.12/Share Est., Sales \$2.881M vs No Sales in Same Qtr. Last Year

Financial news for KITE dated on 2015-05-06: Credit Suisse Analysts Assume Coverage On 10 Biotech Stocks

Financial news for KITE dated on 2015-05-05: Credit Suisse Assumes Kite Pharma at Outperform, Announces \$79.00 PT

Financial news for KITE dated on 2015-04-20: CAR-T Therapy Stocks Hit Hard Following AACR Data

Financial news for KITE dated on 2015-04-20: NeoStem Announces Expanded Cell Therapy Manufacturing Relationship With Kite Pharma

Financial news for KITE dated on 2015-04-17: It's A Big Weekend For Biotech

Financial news for KITE dated on 2015-04-15: Kite Pharma Is Up Because Of This Slideshow

Financial news for KITE dated on 2015-04-15: Kite Pharma Shares Rise 5% Premarket; Kite Presenting Now at 2015 Jefferies Immuno-Oncology Summit in Boston

Financial news for KITE dated on 2015-03-27: Credit Suisse Sees Solid Q4 Earnings For Kite Pharma

Financial news for KITE dated on 2015-03-26: Kite Pharma Reports Q4 EPS - \$0.33 Vs Est -\$0.20

Financial news for KITE dated on 2015-03-17: Kite Pharma Strengthens Its T Cell Receptor Cancer Gene Therapy Platform Through Acquisition of T-Cell Factory B.V.

Financial news for KITE dated on 2015-03-02: Kite Pharma Expands Its Research and Development Collaboration With the National Cancer Institute to Develop a Next

## Generation of Cancer Immunotherapy Products for Solid Tumors

Financial news for KITE dated on 2015-02-23: Biotech Stocks Moving Higher

Financial news for KITE dated on 2015-02-23: Kite Pharma Spikes to High on Volume

Financial news for KITE dated on 2015-02-01: Biotech Breakdown: Market Breaks...Gilead, Kite Pharma & Biogen Idec Worth Watching

Financial news for KITE dated on 2015-01-30: Stocks That Battle Cancer Were The Best-Performing Biotechs In January

Financial news for KITE dated on 2015-01-22: Kite Pharma Announces Expanded Agreement with Tel Aviv Sourasky Medical Center

Financial news for KITE dated on 2015-01-15: Kite CEO Says Company Well-Capitalized

Financial news for KITE dated on 2015-01-15: Kite Pharma Presenting at JP Morgan Healthcare Conference

Financial news for KITE dated on 2015-01-15: Kite CEO Says Learning from Gilead's Pricing Playbook for their Own Experimental Cancer Treatment -Reuters

Financial news for KITE dated on 2015-01-15: 10 Biotech Stories You Might've Missed This Week

Financial news for KITE dated on 2015-01-15: Hearing Unconfirmed Market Chatter Alta Partners Making Distribution to LP's

Financial news for KITE dated on 2015-01-13: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4

Financial news for KITE dated on 2015-01-13: Benzinga's Top #PreMarket Gainers

Financial news for KITE dated on 2015-01-12: A Look At 3 Biotech Stocks With Upside Potential

Financial news for KITE dated on 2015-01-09: Benzinga's Top Initiations

Financial news for KITE dated on 2015-01-09: Mizuho Securities Initiates Kite Pharma With Buy

Financial news for KITE dated on 2015-01-09: Mizuho Securities Initiates Coverage on Kite Pharma at Buy, Announces \$90.00 PT

Financial news for KITE dated on 2015-01-07: Kite Pharma Announces Exclusive License With National Institutes of Health

Financial news for KITE dated on 2015-01-06: Kite Pharma Reports Orphan Drug Designation Granted in EU For KTE-C19, Filed IND Application with FDA

Financial news for KITE dated on 2015-01-06: UPDATE: Credit Suisse Raises Price Target On Kite Pharma On AMGN Deal

Financial news for KITE dated on 2015-01-06: Canaccord Genuity Maintains Buy on Kite Pharma, Raises PT to \$90.00

Financial news for KITE dated on 2015-01-05: Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies

Financial news for KITE dated on 2015-01-02: Benzinga's Volume Movers

Financial news for KITE dated on 2015-01-02: Morning Market Movers

Financial news for KITE dated on 2015-01-02: 4 Stocks Trending On Social Media This Friday

Financial news for KITE dated on 2015-01-02: Benzinga's Top #PreMarket Gainers

Financial news for KITE dated on 2015-01-02: UPDATE: Credit Suisse Raises PT On Kite Pharma On Strong Outlook For CAR-T

Financial news for KITE dated on 2015-01-02: Credit Suisse Maintains Outperform on Kite Pharma, Raises PT to \$71.00

Financial news for KITE dated on 2014-12-30: Kite Pharma Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

Financial news for KITE dated on 2014-12-22: UPDATE: Kite Pharma Submits Investigational New Drug Application

Financial news for KITE dated on 2014-12-22: Kite Pharma Submits Investigational New Drug Application for Phase 1/2 Trial of KTE-C19, Anti-CD19 Chimeric Antigen Receptor

Financial news for KITE dated on 2014-12-10: Kite Pharma Prices 3.485M Share Offering @\$54.00/Share

Financial news for KITE dated on 2014-12-10: Kite Pharma Breaks Out, Again

Financial news for KITE dated on 2014-12-09: Amended S-1 Filing from Kite Pharma Shows Offer for 3M Common Shares

Financial news for KITE dated on 2014-11-26: S-1 from Kite Pharma Shows Registration for \$138M Common Stock Offering

Financial news for KITE dated on 2014-11-17: Jefferies Maintains Buy on Kite Pharma, Raises PT to \$46.00

Financial news for KITE dated on 2014-11-17: Kite Pharma Reports Positive Opinion for Orphan Drug Designation in EU for KTE-C19

Financial news for KITE dated on 2014-11-14: Kite Pharma Reports Q3 EPS of \$(0.24) vs \$(0.23) Est

Financial news for KITE dated on 2014-11-11: The Institutional Money's No. 1 Biotech Stock

Financial news for KITE dated on 2014-10-28: Benzinga's Top Initiations

Financial news for KITE dated on 2014-10-28: Canaccord Genuity Initiates Kite Pharma With Buy

Financial news for KITE dated on 2014-10-28: Canaccord Genuity Initiates Coverage on Kite Pharma at Buy, Announces \$42.00 PT

Financial news for KITE dated on 2014-10-13: Kite Pharma Reports Patients with Relapsed, Refractory Acute Lymphoblastic Leukemia Showed Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor T Cells

Financial news for KITE dated on 2014-10-02: Shares of Kite Pharma Charging Through \$32, \$33, \$34 Levels as CNBC Was Just Highlighting Call by Guggenheim (New Buy Rating, \$73 Price Target) Earlier

Financial news for KITE dated on 2014-09-23: Kite Pharma Shares Spike Higher

Financial news for KITE dated on 2014-08-27: Kite Pharma Shares Move Higher Ahead of CNBC CEO Appearance

Financial news for KITE dated on 2014-08-26: Kite Pharmaceuticals Releases Positive Non-Hodgkin's Lymphoma Result; iKang Healthcare Disappoints

Financial news for KITE dated on 2014-08-26: DSW Jumps On Upbeat Results; Trina Solar Shares Drop

Financial news for KITE dated on 2014-08-26: Markets Rise; Best Buy Q2 Revenue Misses Street View

Financial news for KITE dated on 2014-08-26: Morning Market Movers

Financial news for KITE dated on 2014-08-26: Benzinga's Top #PreMarket Gainers

Financial news for KITE dated on 2014-08-26: Stocks To Watch For August 26, 2014

Financial news for KITE dated on 2014-08-25: Shares of Kite Pharma Rise as Much as 54% After-Hours Monday on Positive Non-Hodgkin's Lymphoma Trial Results Using KTE-C19

Financial news for KITE dated on 2014-08-25: Kite Pharma Announces Patients With Aggressive Non-Hodgkin's Lymphoma Experience Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor T Cells At The National Cancer Institute

Financial news for KITE dated on 2014-08-15: Credit Suisse Sees Continued Operational Progress For Kite Pharma

Financial news for KITE dated on 2014-08-14: Kite Pharma Reports Q2 EPS Loss Of \$2.27; Revenue of \$17.9M

Financial news for KITE dated on 2014-07-22: Kite Reatly Announces 1 for 4 Split

Financial news for KITE dated on 2014-07-15: UPDATE: Stifel Initiates Coverage On Kite Pharma On Potential Of KTE-C19

Financial news for KITE dated on 2014-07-15: Benzinga's Top Initiations

Financial news for KITE dated on 2014-07-15: Jefferies Initiates Kite Pharma At Buy

Financial news for KITE dated on 2014-07-15: Jefferies Initiates Coverage on Kite Pharma at Buy, Announces \$35.00 PT

Financial news for KITE dated on 2014-07-15: Stifel Nicolaus Initiates Coverage on Kite Pharma at Buy, Announces \$31.00 PT

Financial news for KITE dated on 2014-06-23: Kite Pharma Announces Underwriters Exercised Option for An Additional 1.125M Shares

Financial news for KITE dated on 2014-06-20: IPO Lookout: IPOs Up Double Digits On The Week

Financial news for KITE dated on 2014-06-20: Shares of Kite Pharma Open for Trade at \$25.45/Share, Priced at Just \$17

Financial news for KITE dated on 2014-06-20: PREVIEW: Kite Pharma IPO Scheduled to Open at 10:50 AM ET

Financial news for KITE dated on 2014-06-20: Waiting on 3 IPOs This Morning

Financial news for KITE dated on 2014-06-20: US Stock Futures Flat; Darden Posts Weak Earnings

Financial news for KITE dated on 2014-06-20: Earning, Economic and IPO Calendar for Friday June 20, 2014

Financial news for KITE dated on 2014-06-20: Kite Pharma Prices 7.5M Share IPO at \$17.00/Share

Financial news for KITE dated on 2014-06-16: IPO Lookout: 14 IPOs For The Week Of June 16

Financial news for KITE dated on 2014-06-11: Kite Pharma Expects 6M Share IPO to Price \$12-\$14/Share